Overview

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the sirolimus conversion regimen as compared with the calcineurin inhibitor continuation regimen with regards to renal function in stable liver transplant subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Calcineurin Inhibitors
Cyclosporine
Cyclosporins
Everolimus
Sirolimus
Tacrolimus